About Prof. Yu Xianjun
Prof. Yu Xianjun (虞先濬) is the President of Fudan University Shanghai Cancer Center (FUSCC) and Director of the Department of Pancreatic Surgery — one of China's most authoritative figures in pancreatic oncology. With the highest annual pancreatic surgery volume in Shanghai, Prof. Yu leads a team that combines surgical excellence with cutting-edge multidisciplinary care to deliver outcomes that meet international standards.
Prof. Yu has dedicated over two decades to advancing the surgical and systemic treatment of pancreatic cancer. He has led numerous national and international clinical trials, contributed to the development of China's pancreatic cancer treatment guidelines, and trained a generation of pancreatic surgeons. His work has been published in leading peer-reviewed journals including Annals of Surgery, JAMA Oncology, and Gut.
Clinical Expertise
- Radical pancreatic cancer resection — including complex procedures such as pancreaticoduodenectomy (Whipple procedure), distal pancreatectomy with splenectomy, and total pancreatectomy for multifocal disease
- Minimally invasive & robotic pancreatic surgery — laparoscopic and da Vinci robotic-assisted resections offering reduced blood loss, shorter hospital stay, and faster return to daily life
- Vascular reconstruction — resection and reconstruction of the portal vein or superior mesenteric vein in locally advanced cases, extending surgical eligibility to patients previously deemed inoperable
- Multidisciplinary treatment (MDT) — integrating surgery, chemotherapy, targeted therapy, immunotherapy, and radiotherapy for comprehensive, coordinated cancer management
- Individualized treatment planning — precision oncology approaches tailored to each patient's tumor biology, molecular profiling, staging, and overall health status
- Borderline resectable & locally advanced pancreatic cancer — neoadjuvant strategies (chemotherapy ± radiotherapy) to convert initially unresectable tumors into surgical candidates
- Intraductal papillary mucinous neoplasms (IPMN) & cystic tumors — surveillance and surgical management of premalignant pancreatic lesions
Why Prof. Yu Xianjun?
Pancreatic cancer is one of the most challenging malignancies to treat, requiring a surgeon with both technical mastery and deep oncological expertise. Prof. Yu's position as FUSCC President reflects his standing as a national leader in the field. His department performs the highest volume of pancreatic surgeries in Shanghai, and his team's experience with robotic and minimally invasive techniques offers patients faster recovery with equivalent oncological outcomes.
FUSCC's multidisciplinary tumor board — which Prof. Yu chairs — ensures that every patient's case is reviewed by specialists across surgery, medical oncology, radiology, pathology, and nutrition before a treatment plan is finalized. This integrated approach is particularly valuable for international patients who require a clear, coordinated roadmap from diagnosis to recovery.
For patients with borderline or locally advanced disease, Prof. Yu's team is experienced in designing neoadjuvant regimens that can shrink tumors prior to surgery, significantly improving the chance of achieving clear surgical margins (R0 resection) — the single most important predictor of long-term survival in pancreatic cancer.
Hospital: Fudan University Shanghai Cancer Center (FUSCC)
FUSCC is China's leading dedicated cancer hospital, affiliated with Fudan University School of Medicine. It is consistently ranked among the top oncology centers in Asia, with internationally trained specialists, state-of-the-art surgical suites equipped with the da Vinci Xi robotic system, and a robust clinical trials program. The center sees over 100,000 new cancer patients annually and is a national benchmark for cancer diagnosis and treatment.
FUSCC's Pancreatic Surgery Department is one of the largest and most experienced in China, with a dedicated pancreatic ICU, specialized nursing teams, and a nutritional support program tailored to the unique metabolic demands of pancreatic surgery patients. The department also operates a hereditary pancreatic cancer clinic for patients with BRCA, PALB2, or ATM mutations.
About Pancreatic Cancer
Pancreatic cancer accounts for approximately 3% of all cancers globally but is responsible for 7% of cancer deaths, reflecting its aggressive nature and frequent late-stage diagnosis. It is the 7th leading cause of cancer death worldwide, with rising incidence in Asia. Key facts for international patients:
- Early-stage pancreatic cancer (Stage I–II) has a 5-year survival rate of 20–30% with surgical resection — surgery remains the only curative option
- Robotic and laparoscopic surgery can reduce hospital stay to 5–7 days vs. 10–14 days for open surgery, with significantly less postoperative pain
- Neoadjuvant chemotherapy (FOLFIRINOX, gemcitabine + nab-paclitaxel) can downstage borderline resectable tumors and improve R0 resection rates
- BRCA1/2 and PALB2 mutations are actionable targets — PARP inhibitors (olaparib) are approved for maintenance therapy in platinum-sensitive patients
- KRAS G12C and G12D inhibitors represent an emerging frontier in targeted therapy for pancreatic cancer
- Endoscopic ultrasound (EUS) and high-resolution MRI/MRCP are essential for accurate staging and surgical planning
- Nutritional optimization before and after surgery is critical — pancreatic enzyme replacement therapy (PERT) is routinely prescribed post-resection
What to Prepare Before Your Consultation
To facilitate a productive remote case review or in-person consultation with Prof. Yu's team, international patients should prepare the following documents:
- Recent CT scan or MRI of the abdomen (with contrast, within 3 months) — DICOM files preferred
- Pathology report and biopsy results (if available)
- CA 19-9, CEA, and other relevant tumor marker results
- Complete blood count, liver function tests, and nutritional markers (albumin, prealbumin)
- Summary of prior treatments (chemotherapy regimens, radiation, surgery) with dates and response assessments
- Genetic testing results (BRCA1/2, PALB2, ATM, MSI/MMR status) if available
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking pancreatic cancer treatment at FUSCC with Prof. Yu Xianjun. Our services include:
- Medical record review and remote case assessment before travel
- Direct appointment coordination with Prof. Yu's team, including priority scheduling
- Translation of imaging reports, pathology findings, and treatment plans (English, Arabic, Russian, and other languages)
- Accommodation, airport transfer, and in-hospital accompaniment by a dedicated case manager
- Interpretation during consultations and surgical consent discussions
- Post-treatment follow-up coordination and remote consultation support after returning home
To begin your consultation, contact our team:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 Kommentare